排序方式: 共有58条查询结果,搜索用时 15 毫秒
1.
BACKGROUND: Adjuvant postoperative treatment with 5-fluorouracil (5-FU) and leucovorin in curatively resected stage III colon cancer significantly reduces the risk of cancer recurrences and improves survival. The impact of 5-FU plus leucovorin on survival and tumor recurrence was analyzed in a long-term follow-up study in comparison with the effects of 5-FU plus levamisole in the prospective multicenter trial adjCCA-01. PATIENTS AND METHODS: Patients with a curatively resected stage III (International Union Against Cancer) colon cancer were stratified according to tumor, node and grading category and randomly assigned to receive one of the two adjuvant treatment schemes: 5-FU 400 mg/m2 body surface area intravenously in the first chemotherapy course, then 450 mg/m2 x 5 days, plus leucovorin 100 mg/m2, 12 cycles (arm A), or 5-FU plus levamisole (Moertel scheme; arm B). RESULTS: Six hundred and eighty (96.9%) of 702 patients enrolled into this study were eligible. To date, 261 patients have died, 117 on arm A and 144 on arm B (P = 0.007). After a median follow-up time of 82 months, the 5-FU plus leucovorin combination significantly improved disease-free survival [79.8 months in arm A versus 69.3 months in arm B (P = 0.012)] and significantly increased median overall survival (88.9 months in arm A versus 78.6 months in arm B; P = 0.003). Adjuvant treatment with 5-FU plus levamisole as well as 5-FU plus leucovorin was generally well tolerated; only a minority of patients experienced grade 3 and 4 toxicities. CONCLUSIONS: After curative resection of a stage III colon cancer, adjuvant treatment with 5-FU plus leucovorin is generally well tolerated. This long-term follow-up study demonstrates that adjuvant treatment with 5-FU plus leucovorin given for 12 cycles is significantly more effective than 5-FU plus levamisole (Moertel scheme) in reducing tumor relapse and improving survival. 相似文献
2.
3.
Falchook GS Long GV Kurzrock R Kim KB Arkenau TH Brown MP Hamid O Infante JR Millward M Pavlick AC O'Day SJ Blackman SC Curtis CM Lebowitz P Ma B Ouellet D Kefford RF 《Lancet》2012,379(9829):1893-1901
4.
Gerhard H Scholz Eva Hagemann Cord Arkenau Lothar Engelmann Peter Lamesch Dierk Schreiter Manfred Schoenfelder Derk Olthoff Ralf Paschke 《Thyroid》2003,13(10):933-940
Early thyroidectomy is the treatment of choice for thyrotoxic storm in patients with thyroid autonomy often induced by iodine. However, older patients who are mostly affected by this condition often have underlying chronic cardiopulmonary diseases, apparently contradicting surgical intervention. The published evidence for suitable treatment strategies in these patients is limited. We report the outcome of a series of older critically ill patients who were treated by thyroidectomy because of thyrotoxic storm. We retrospectively analyzed the outcome of 10 patients (4 males, 6 females; 70 years of age, range, 54-79, Burch-Wartofsky point scale, 61; range, 40-85) with thyrotoxic storm, thyroid autonomy, and severe cardiorespiratory and renal failure with cardiac arrhythmia, coronary artery or chronic obstructive pulmonary disease, or acute inflammation. Thyroidectomy was performed for the following reasons: symptoms of thyrotoxic storm deteriorated or did not improve within 24-48 hours despite intensive medical treatment, or patients developed thionamide-induced agranulocytosis or severe thrombocytopenia. All patients with severe accompanying diseases survived thyroidectomy (early post-operative mortality, 0%). The two oldest patients died 2-3 weeks after thyroidectomy because of myocardial infarction or respiratory failure (late postoperative mortality, 20%). In contrast, in the few previous reports of patients who underwent thyroidectomy for thyrotoxic storm and severe accompanying diseases (n = 7), late postoperative mortality was 43%. The overall mortality for all reported patients including our own, who underwent thyroidectomy for thyrotoxic storm with and without severe accompanying disease (n = 49) was 10%. Our results suggest that early total thyroidectomy should be considered as the method of choice for older, chronically ill patients with thyrotoxic storm complicated by cardiorespiratory and renal failure, especially if high-dose thionamide treatment, iopanoic acid, glucocorticoids, and intensive care fail to improve the patient's conditions within 12-24 hours. 相似文献
5.
Oxaliplatin,fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial 总被引:3,自引:0,他引:3
Nehls O Klump B Arkenau HT Hass HG Greschniok A Gregor M Porschen R 《British journal of cancer》2002,87(7):702-704
We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas. The disease control rate (responses and stable disease) was 56% (95% confidence interval, 29-84%) and the median overall survival time was 9.5 months (range 0.9-26.8+). Therefore, this regimen might be active in biliary adenocarcinomas with further evaluation necessary. 相似文献
6.
Baldus SE Mönig SP Arkenau V Hanisch FG Schneider PM Thiele J Hölscher AH Dienes HP 《Annals of surgical oncology》2002,9(9):887-893
Background MUC5AC represents a mucin peptide core expressed in normal gastric epithelia. Its presence in gastric carcinomas was previously
described as a characteristic of gastric differentiation.
Methods MUC5AC reactivity was investigated by immunohistochemistry and correlated with clinicopathological variables in a large series
(n=200) of gastric carcinomas.
Results A statistically significant association between MUC5AC positivity and parameters of cancer progression (pTNM staging and grading)
could not be observed. However, MUC5AC exhibited correlations with certain subtypes of histopathological differentiation.
A significant reduction of MUC5AC expression was evident in mucinous and undifferentiated carcinomas according to the World
Health Organization classification, as well as in type III cancers according to the Goseki classification system. Furthermore,
reduced MUC5AC reactivity (confined to up to 35% of the tumor area) was significantly correlated with an unfavorable prognosis
of all patients in univariate and multivariate analysis. The same association could be observed in the subgroup of pTNM stage
I patients (n=60).
Conclusions A significant reduction of gastric differentiation as reflected by MUC5AC immunoreactivity represents a marker of worse survival
probability in gastric cancer. Finally, reduced MUC5AC positivity defines a high-risk subgroup of pTNM stage I patients. 相似文献
7.
S Postel-Vinay H-T Arkenau D Olmos J Ang J Barriuso S Ashley U Banerji J De-Bono I Judson S Kaye 《British journal of cancer》2009,100(9):1373-1378
Phase-I trials traditionally involve dose-escalation to determine the maximal tolerated dose (MTD). With conventional chemotherapy, efficacy is generally deemed to be dose-dependent, but the same may not be applicable to molecularly targeted agents (MTAs). We analysed consecutive patients included in Phase-I trials at the Royal Marsden Hospital from 5 January 2005 to 6 June 2006. We considered only trials of monotherapy MTAs in which the MTD was defined. Three patient cohorts (A, B, and C) were identified according to the dose received as a percentage of the final trial MTD (0–33%, 34–65%, >66%). Potential efficacy was assessed using the non-progression rate (NPR), that is, complete/partial response or stable disease for at least 3 months by RECIST. A total of 135 patients having progressive disease before enrolment were analysed from 15 eligible trials. Median age was 57 years (20–86); male : female ratio was 1.8 : 1. Cohort A, B, and C included 28 (21%), 22 (16%), and 85 (63%) patients; NPR at 3 and 6 months was 21% and 11% (A), 50% and 27% (B), 31% and 14% (C), respectively, P=0.9. Median duration of non-progression (17 weeks; 95% CI=13–22) was not correlated with the MTD level, P=0.9. Our analysis suggests that the potential for clinical benefit is not confined to patients treated at doses close to the MTD in Phase-I trials of MTAs. 相似文献
8.
Colorectal cancer (CRC) is one of the most common cancers in the Western world, with > 500,000 new cases diagnosed each year. One of the strongest risk factors for colon cancer is age. The incidence rates rise from 10 in 100,000 at age 40-45 years to 300 in 100,000 at age 75-80 years, with the median age at diagnosis of CRC being 71 years. With the general demographic shift toward an aging population, the number of people aged > 65 years is expected to increase. This article reviews the development of treatment for elderly patients with metastatic CRC, from single-agent fluoropyrimidines to combination therapies. 相似文献
9.
Andre T. Brunetto Joo Ern Ang David Olmos Daniel Tan Jorge Barriuso Hendrik-Tobias Arkenau Timothy A. Yap L. Rhoda Molife Udai Banerji Johann de Bono Ian Judson Stan Kaye 《European journal of cancer (Oxford, England : 1990)》2010,46(15):2739-2745
BackgroundUnplanned hospital admissions (UHAs) in the context of oncology Phase I trials are important, yet rarely reported.MethodsAll patients admitted to the Royal Marsden Hospital Phase I clinical trials unit during February and March of 2005–2007 were included. The patient-, admission- and trial-related variables were collected. Correlations were sought between the occurrence of UHAs and the baseline patient/trial-related characteristics.ResultsOf the 308 admissions involving 177 patients, UHAs constituted 21% of all the admissions and 38% of the total bed occupancy. The majority of UHAs were cancer related (78%) and their occurrence was associated with a significant early patient attrition. Using multivariate analysis, the factors significantly associated with UHAs included age >60 years (RR 2.32, confidence interval (CI)-95% 1.12–4.81), ?3 metastatic sites (RR 3.26, CI-95% 1.54–6.90) and LDH > ULN (RR 2.18, CI-95% 1.06–4.46), with albumin <35 g/dL trending to significance (p = 0.052). The trials that contained cytotoxic chemotherapy incurred disproportionately higher rates of admissions (69.5%) than the trials that did not.ConclusionsUHAs constitute a substantial workload and impact on the speed and cost of, as well as resource allocation in Phase I oncology trials. The majority of UHAs are cancer rather than treatment related. The risk stratification to guide patient selection may help reduce the incidence of UHAs. 相似文献
10.